Voss, Linn
Yilmaz, Kiymet
Burkard, Lea
Vidmar, Janja
Stock, Valerie
Hoffmann, Ute
Pötz, Oliver
Hammer, Helen Sophie
Peiser, Matthias
Braeuning, Albert
Löschner, Katrin
Böhmert, Linda
Sieg, Holger http://orcid.org/0000-0002-0593-0173
Funding for this research was provided by:
Robert Bosch Stiftung
Bundesinstitut für Risikobewertung
Article History
Received: 22 July 2020
Accepted: 2 September 2020
First Online: 10 September 2020
Compliance with ethical standards
:
: The manuscript does not contain clinical studies or patient data.
: The authors declare the following competing financial interest(s): Oliver Pötz is shareholder of SIGNATOPE GmbH. SIGNATOPE offers assay development and service using MS-based immunoassay technology. Apart from that, the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.